SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine Development Financed by the European Union
Thursday, March 12, 2026
2 min read
Canonical SourceSouth Korea
Summary Only
What Changed
SK bioscience, IDT Biologika, and Vaxxas selected by the European Union for a project to develop next-generation influenza vaccines, signaling a new collaborative effort in vaccine innovation.
Sigvera Intelligence
Source Trust:Discovery
Source Report
SK Bioscience, with partners IDT Biologika and Vaxxas, was selected for an EU-financed project to develop a next-generation influenza vaccine.
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsPartnership
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://www.prnewswire.com/news-releases/sk-bioscience-idt-biologika-and-vaxxas-selected-for-next-generation-influenza-vaccine-development-financed-by-the-european-union-302697969.html
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In